Autolus Therapeutics (AUTL) Earnings Date, Estimates & Call Transcripts $3.14 -0.12 (-3.68%) (As of 12:02 PM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Autolus Therapeutics Latest Earnings SummaryUpcoming Q4 Earnings DateMar. 13EstimatedActual EPS (Nov. 12) -$0.31 Missed By -$0.10 Consensus EPS (Nov. 12) -$0.21 Autolus Therapeutics issued Q3 2024 earnings on November 12, 2024, reporting an EPS of -$0.31, which missed analysts' consensus estimates of -$0.21 by $0.10. With a trailing EPS of -$1.21, Autolus Therapeutics' earnings are expected to grow next year, from ($0.94) to ($0.76) per share. Conference Call TranscriptConference Call AudioEarnings Press ReleaseEarnings Slide DeckPowered by AUTL Upcoming EarningsAutolus Therapeutics' next earnings date is estimated for Thursday, March 13, 2025, based off prior year's reporting schedules. Get Autolus Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Autolus Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataAUTL Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.AUTL Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Porter & CompanyThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. Autolus Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241-$0.30-$0.30-$0.30Q2 20241-$0.29-$0.29-$0.29Q3 20241-$0.28-$0.28-$0.28Q4 20241-$0.33-$0.33-$0.33FY 20244-$1.20-$1.20-$1.20Q1 20251-$0.24-$0.24-$0.24Q2 20251-$0.25-$0.25-$0.25Q4 20251-$0.20-$0.20-$0.20 Autolus Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 3/13/2025(Estimated)-------11/12/2024Q3 2024-$0.21-$0.31 -$0.10-$0.31$0.40M-8/8/2024Q2 2024-$0.19-$0.22 -$0.03-$0.22--5/17/2024Q1 2024-$0.10-$0.24 -$0.14-$0.24$50.00M$10.09M3/14/2024Q4 2023-$0.26-$0.44 -$0.18-$0.44--11/2/2023Q3 2023-$0.24-$0.26 -$0.02-$0.26$2.00M$0.41M8/3/2023Q2 2023-$0.22-$0.26 -$0.04-$0.26-- Get the Latest News and Ratings for AUTL and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Autolus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 5/4/2023Q1 2023-$0.28-$0.23+$0.05-$0.23$1.09M$1.29M3/7/2023Q4 2022-$0.31-$0.23+$0.08-$0.23$4.50M$3.83M Autolus Therapeutics Earnings - Frequently Asked Questions When is Autolus Therapeutics's earnings date? Autolus Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 13th, 2025 based off last year's report dates. Learn more on AUTL's earnings history. Did Autolus Therapeutics beat their earnings estimates last quarter? In the previous quarter, Autolus Therapeutics (NASDAQ:AUTL) missed the analysts' consensus estimate of ($0.21) by $0.10 with a reported earnings per share (EPS) of ($0.31). Learn more on analysts' earnings estimate vs. AUTL's actual earnings. How can I listen to Autolus Therapeutics's earnings conference call? The conference call for Autolus Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Autolus Therapeutics's conference call transcript? The conference call transcript for Autolus Therapeutics's latest earnings report can be read online. Read Transcript How much revenue does Autolus Therapeutics generate each year? Autolus Therapeutics (NASDAQ:AUTL) has a recorded annual revenue of $1.70 million. How much profit does Autolus Therapeutics generate each year? Autolus Therapeutics (NASDAQ:AUTL) has a recorded net income of -$208.38 million. AUTL has generated -$1.21 earnings per share over the last four quarters. What is Autolus Therapeutics's EPS forecast for next year? Autolus Therapeutics's earnings are expected to grow from ($0.94) per share to ($0.76) per share in the next year. More Earnings Resources from MarketBeat Related Companies MoonLake Immunotherapeutics Earnings Results ImmunityBio Earnings Results Agios Pharmaceuticals Earnings Results Merus Earnings Results Arrowhead Pharmaceuticals Earnings Results Xenon Pharmaceuticals Earnings Results Zai Lab Earnings Results Vera Therapeutics Earnings Results Verona Pharma Earnings Results Edgewise Therapeutics Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings Report This company will win the AI race (Ad)Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. This page (NASDAQ:AUTL) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autolus Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Autolus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
